drugset / Trial / NCT03398434
Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
RandomizedParallel-groupSingle-blindBasic science
Summary
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of MAA868 compared to apixaban in patients with atrial fibrillation.
Timeline
- Start
- 2018-10-16
- Primary completion
- 2019-11-28
- Completion
- 2020-01-30
Outcome
Outcome not reported
Stopped (Enrollment): “Trial cancelled before First Patient First Visit (no patient enrolled)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apixaban | Small molecule | 5 mg | — |
| Subject | MAA868 | Unknown | — | Subcutaneous |